ALNY vs XPER · P/E 76, rev $1.29B vs rev $448.1M
Alnylam Pharmaceuticals Inc (ALNY) versus Xperi Corp (XPER) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Xperi Corp (XPER) is a software - application company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported XPER revenue for 2025-12-31 was $448.1M. Net income was -$56.3M. Revenue was down 9.2% from 2024-12-31 to 2025-12-31. XPER currently screens at market cap $367.8M.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. XPER currently screens at market cap $367.8M.
Not investment advice. Open the ALNY and XPER stock pages for the full models.
Not investment advice.